Trial Profile
An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Feb 2020 Status changed from active, no longer recruiting to completed.
- 19 Nov 2019 Planned End Date changed from 12 Nov 2019 to 5 Dec 2019.
- 19 Nov 2019 Planned primary completion date changed from 12 Nov 2019 to 5 Dec 2019.